Granules India net profit rises 71 percent to Rs 164 crore in Q2

Published On 2020-10-21 06:38 GMT   |   Update On 2020-10-21 06:38 GMT
Advertisement

New Delhi: Drug firm Granules India on Tuesday reported a 70.82 per cent rise in its consolidated net profit to Rs 163.63 crore for the second quarter ended September 30, mainly on account of robust sales.

The company had posted a net profit of Rs 95.79 crore for the corresponding period previous fiscal, Granules India said in a BSE filing.

Consolidated revenue from operations stood at Rs 858.12 crore for the quarter under consideration. It was Rs 699.53 crore in the same period a year ago, it added.

Advertisement

"I am pleased to announce second consecutive robust performance by all our business segments, fuelled the 22.7 per cent growth in Q2FY21 revenues to Rs 858 crore," Granules India Chairman and MD Krishna Prasad Chigurupati said.

Read also: Granules India Dexmethylphenidate HCl ER capsules get USFDA approval to treat ADHD

The company''s Board has declared a second interim dividend of 25 paise per equity share of Re 1 each, the filing said.

Shares of Granules India Ltd were trading at Rs 393.55 per scrip on BSE, up 0.54 per cent from its previous close.

Read also: Granules India gets USFDA green flag for sleep aid drugs Naproxen Sodium, Diphenhydramine Hydrochloride Tablets



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News